Centre for Biologics Evaluation and Research (CBER)

The Centre for Biologics Evaluation and Research (CBER) is a division within the U.S. Food and Drug Administration (FDA) responsible for overseeing the safety, effectiveness, and quality of biological products, such as vaccines, blood products, gene therapies, and cellular treatments. CBER reviews and approves these products before they reach the public to ensure they are safe and beneficial. It also monitors their use after approval, addressing any safety concerns that may arise. Its goal is to protect public health by ensuring available biological products are safe, effective, and meet quality standards.